Vir Biotechnology SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Entry into a material definitive agreement · Other events · Financial statements and exhibits
AI summary, unreviewedVir Biotechnology prices 15,000,000-share public offering at $10.00 per share for $150 million gross proceeds
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedVir Biotechnology Phase 3 ECLIPSE 1 Hits Primary Endpoint at 44% Response, Key Secondary at 79% Undetectable Virus
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedVir Biotechnology Q3 2026 EPS of -$0.57 beats -$0.75 consensus, but revenue of -$0.2 million misses $1.4 million estimate
Departure/appointment of directors or officers
AI summary, unreviewedVir Biotechnology Expands Board to Nine Members with Appointment of Suzanne Topalian, M.D.
Unregistered sales of equity securities · Other events · Financial statements and exhibits
Other events · Financial statements and exhibits
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
Results of operations and financial condition · Financial statements and exhibits
Departure/appointment of directors or officers